Form 4: CCRN Executive Granted Restricted Stock Post-Merger Termination

Cynthia Ann Grieco, VP, Corporate Treasurer of Cross Country Healthcare Inc., was granted 11,288 restricted shares of common stock following a merger agreement termination.

Summary

• Cynthia Ann Grieco, VP, Corporate Treasurer of Cross Country Healthcare Inc. (CCRN), acquired 11,288 shares of common stock on December 18, 2025.
• These shares are Restricted Stock Awards (RSAs) granted with an acquisition price of $0, indicating they are part of an equity compensation plan.
• The RSAs will vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028.
• The Compensation Committee approved the grant date of December 18, 2025, instead of March 31, 2025, following the termination of a Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025.
• The subsequent vesting dates (March 31) are set to coincide with the vesting dates of the Company's previously granted RSAs.
• Following this transaction, Ms. Grieco directly beneficially owns 17,627 shares of common stock.

Sentiment

Score: 6

Explanation: The grant of restricted stock to a key executive is generally positive for aligning interests and retention. However, the underlying reason for the adjusted grant date (merger termination) introduces a degree of uncertainty regarding the company's strategic direction, preventing a higher score. The transaction itself is a routine compensation event.

Positives

• The grant of restricted stock to a key executive (VP, Corporate Treasurer) aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule encourages executive retention and sustained performance over time.

Risks

• The termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025, could introduce strategic uncertainty or impact the company's future growth trajectory.

Future Outlook

The vesting schedule for the restricted shares extends through March 31, 2028, aligning future executive incentives with long-term company performance. The company's Compensation Committee adjusted the grant date following a merger termination, suggesting a recalibration of executive incentives post-strategic event.

Management Comments

• "The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025."
• "After the initial vesting date 12 months from the grant date, the remaining RSAs will vest on March 31 of the two subsequent years to coincide with the vesting dates of the Company's previously granted RSAs."

Industry Context

This Form 4 details an executive compensation event, specifically a restricted stock grant, which is a common practice across industries to align executive interests with shareholder value. The adjustment of the grant date due to a merger termination highlights the dynamic nature of corporate strategy and its immediate impact on executive incentive structures, a scenario frequently observed in the healthcare staffing and services sector where M&A activity can be significant.

Comparison to Industry Standards

• Restricted Stock Awards (RSAs) with multi-year vesting schedules are a standard component of executive compensation packages in the healthcare staffing industry, similar to practices at companies like AMN Healthcare Services (AMN) or HealthEquity (HQY), aiming to promote long-term retention and performance.
• A $0 acquisition price for granted shares is typical for equity compensation, reflecting the incentive nature rather than a direct purchase.
• The adjustment of grant dates post-significant corporate events, such as merger terminations, is a common governance practice to ensure compensation plans remain aligned with the company's revised strategic direction, a flexibility seen across various publicly traded entities.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with long-term shareholder value due to multi-year vesting of restricted stock. However, the underlying merger termination could be a concern regarding strategic direction.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and morale.

Next Steps

• Vesting of the first installment of restricted shares on December 18, 2026.
• Vesting of the second installment of restricted shares on March 31, 2027.
• Vesting of the third installment of restricted shares on March 31, 2028.

Key Dates

Recommendation

This Form 4 reports a routine restricted stock grant to an executive, which is a standard compensation practice aimed at aligning executive interests with long-term performance. While the context of a terminated merger is noted, this filing alone does not provide sufficient new fundamental information to warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not present a strong case for buying or selling based solely on this compensation event.

Keywords

Cross Country Healthcare, CCRN, Restricted Stock, RSA, Executive Compensation, Insider Transaction, Form 4, Cynthia Ann Grieco, Merger Termination